Zobrazeno 21 - 30
of 15 348
pro vyhledávání: ''
Autor:
Kosei Hirakawa, Yuki Okazaki, Masatsune Shibutani, Shinichiro Kashiwagi, Masaichi Ohira, Wang En, Yasuhito Iseki, Tatsunari Fukuoka
Publikováno v:
Anticancer Research. 41:6211-6216
Background/aim Recently, trifluridine/tipiracil (FTD/TPI) treatment was established as a later-line treatment for metastatic colorectal cancer (mCRC). However, FTD/TPI treatment is frequently associated with hematological toxicity. The aim of this st
Publikováno v:
Plastic & Reconstructive Surgery. 148:27S-31S
Background Photoaging is premature skin aging resulting from oxidative stress generated by exposure to solar radiation. A key clinical feature is solar lentigines, areas of hyperpigmentation on sun-exposed skin. Skin pigmentation is determined by cro
Publikováno v:
Breast Cancer Research and Treatment
Purpose Breast cancer survivors take vitamins and supplements to bolster their general health and to decrease the risk of cancer recurrence. Healthcare providers are frequently unaware of their patients non-prescription supplement use. The aim of thi
Autor:
Muzaffar H. Qazilbash, Mehdi Hamadani, Samantha Jaglowski, Walter Hanel, Madiha Iqbal, Ankit Kansagra, Beth Christian, Ravi Narra, Sairah Ahmed, Mohamed A. Kharfan-Dabaja, Qiuhong Zhao, Krina K. Patel, Narendranath Epperla, Farrukh T. Awan
Publikováno v:
Hematological Oncology. 40:49-57
Waldenstrom macroglobulinemia (WM) is a rare B-cell lymphoproliferative malignancy. Autologous hematopoietic cell transplantation (auto-HCT) is considered in a subset of WM patients with relapsed disease. While registry data has shown a benefit for a
Publikováno v:
Biomarkers. 26:780-787
Introduction The Nrf2 (nuclear factor erythroid 2-like 2; NFE2L2)/Keap1 (Kelch-like ECH-associated protein 1) pathway and the TXN (thioredoxin)/GSH (glutathione) system interact mutually and regulate cellular redox with impacts on cancer metastasis a
Autor:
Boya Zhang, Jianpeng Yu, Yuanjie Niu, Zhiqun Shang, Qi Li, Shimiao Zhu, Mingpeng Zhang, Yanjie Yang
Publikováno v:
Oncogene
Castration-resistant prostate cancer (CRPC) is a highly malignant type of advanced cancer resistant to androgen deprivation therapy. One of the important mechanisms for the development of CRPC is the persistent imbalanced regulation of AR and AR spli
Autor:
Marco Pavesi, Moisés Mira Flores, Aurea Duran, Josep Gumà, Alessandra Pranzo, Alexis Serikoff, Bernard Rappe, Angus Robinson, Serena Hilman, Benoit Baron, Louis-Marie Dourthe, D. Mott, Steven Joniau, M. Herdman, Stéphane Mallick, Roberto Bordonaro, Maria De Santis, Ugo De Giorgi, Heather Payne
Publikováno v:
International Journal of Cancer. 150:837-846
In randomized clinical trials, the androgen-receptor inhibitor enzalutamide has demonstrated efficacy and safety in metastatic castration-resistant prostate cancer (mCRPC). This study captured efficacy, safety and patient-reported outcomes (PROs) of
Autor:
Stefano Mangiola, Jeremy Grummet, Michael Kerger, Paul Ruljancich, Ryan Stuchbery, David Clarke, Justin S. Peters, Andrew Ryan, Niall M. Corcoran, Phillip Parente, Nicholas Howard, Christopher M. Hovens, Natalie Kurganovs, Sam Norden, Anthony J. Costello, Anne Ngyuen, Corrina A Grima, Patrick McCoy, Geoff Macintyre, Philip Dundee, Marek Cmero, Ken Chow
Publikováno v:
JCO Precision Oncology
PURPOSE Androgen receptor (AR) signaling is important in prostate cancer progression, and therapies that target this pathway have been the mainstay of treatment for advanced disease for over 70 years. Tumors eventually progress despite castration thr
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 24, Pp 8789-8798 (2021)
Cancer Medicine, Vol 10, Iss 24, Pp 8789-8798 (2021)
Preclinical observations that killing of chronic lymphocytic leukemia (CLL) cells was dexamethasone (DEX) were enhanced by concomitant inhibition of Bruton’s tyrosine kinase and janus kinases (JAKs) motivated a phase II trial to determine if clinic
Autor:
Douglas S. Lee, Anca Prica, Peter C. Austin, Andrea Pang, Paaladinesh Thavendiranathan, Husam Abdel-Qadir, Darryl P. Leong, Oscar Calvillo-Argüelles, Nasruddin Sabrie, Kumaraswamy Nanthakumar
Publikováno v:
Journal of Clinical Oncology. 39:3453-3462
PURPOSE Ibrutinib reduces mortality in chronic lymphocytic leukemia (CLL). It increases the risk of atrial fibrillation (AF) and bleeding and there are concerns about heart failure (HF) and central nervous system ischemic events. The magnitude of the